The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
With tongue in cheek, a word of warning to ORuin. " ... would like some money put away for the future": it becomes hard to *sell* an investment as successful as Draper Esprit [says one who to date has made, I think, 18 separate purchases and zero sells].
W13Ken: couldn't agree more! Your scepticism about comments on bulletin boards is well justified, yet this particular one is well respected: by me at least!
With sp boost this morning we shareholders should be smiling. Time perhaps to ask: could someone explain please the difference in the terms "ordinary" and "automatic" seen in the table of recent trades. Thanks!
The chart clearly shows the sp will fluctate, sometimes rising and at other times falling. But then, we all knew that anyway.
Lots of long words in the directors' statements but "nothing much changes".
Steph, just followed your lead, could resist with sp below 800.
So pleased to have you on this BB. Not just informative but your optimism makes a welcome change from the derampers found on many other BBs. And in case you're wonering, I share your optimism.
RR: yes, the chemo news was exciting. That road to commercial success is however quite long, probably mid 2023 at best, and many potential pot-holes along the way.
This certainly is a lively BB. My first AVCT post [07.01 today], expressing disappointment with the lack of commercial information within yesterday’s webinar, and I take stick.
Should a “one horse post” go into the filter book? Every journey starts with a single step.
Is my nervousness reflected in the MM’s since the webinar? Without a doubt!
As for “F ing off” with my imaginary shares; and will I “jog right on”? No, not yet, my investment(s) which are real need direction and these BBs help (even if not all of the postings are useful).
But to the many posters sticking to the facts, thanks, and good luck!
I was impressed by the science; very impressed. But there was very little to excite on the commercial front and it's the commerce, not the science, which will determine where the share price goes. So in my eyes this was another missed opportunity. AS is no fool so one has to ask why: it makes me nervous!
Several posters on this BB are in GROW for the long term. Whilst the next year is unlikely to match the past 12 months the GROW team have a good record so prospects remain rosy!
As they say "don't hold your breath"! I'm beginning to wonder if all the promise will ever materialise myself.
As a friend said to me when I started stock market investing "you can only lose 100%"! The implication was that gains can be bigger.
As with other posters on this BB, GROW is the major constituent of my share portfolio (approaching 25%); and I'm content to hold my position. And whilst I value Steph's many contributions here - keep them coming - I'm less optimistic in thoughts on premium to NAV. Until further valuations I think sp = low to mid 800s is about right. As for Cazoo, it's a concept easy to mimic and there's competition; only time will tell!
Are Deepverge seen as competitors or partners of Avacta?
Sorry about the typo: should be AVCT!
As a new-ish shareholder in DVRG I'm unsure about AVDT: are they competitors or partners?
Noted a £4M sale at 12.02 today: it wasn't me!
Topped up yesterday @ 777p and now approaching my self-imposed 20% limit. Would I be right in thinking GROW is likely to be promoted to the FTSE(250) at the next review in March; and this would result in some limited buying by tracker funds?
http://www.stockchallenge.co.uk/ftse.php
Me too! It might seem odd but I'd be disappointed with the short-term lift arising from a buy-out.